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Within the past century, a number of
‘‘emerging viruses’’ with pathogenic prop-
erties, such as HIV-1, SARS-CoV, and
several novel reassortments of influenza A,
have entered the human population on a
large scale. However, novel pathogenic
viral infections of humans are not unique
to modern history. ‘‘Paleovirology’’ is the
study of ancient extinct viruses (called
‘‘paleoviruses’’) and the effects that these
agents have had on the evolution of their
hosts. Thus far, the study of these viruses
has mostly been limited to endogenous
retroviruses that can be directly identified
from their remnants in host genomes.
However, one can infer the existence of
other paleoviruses from their evolutionary
pressures on host genes. We suggest that
selection to survive the pathogenic effects
of these viruses has shaped our repertoire
of antiviral defenses in ways that impact
our resistance or susceptibility to modern-
day emerging viruses.
Unearthing Signs of Ancient
Viral Infections
The human genome is a living docu-
ment of ancient and now extinct viruses.
Indeed, DNA of retroviral origin makes up
8% of human genome sequence. Retrovi-
ruses are RNA viruses that replicate
through a DNA intermediate called a
provirus, which becomes integrated into
the host cell chromosome. Usually such
integrations occur in somatic cells, but
when integration of the provirus occurs in
a germ cell, an endogenous retrovirus can
be inherited as part of the genome. If these
germline insertions become fixed within a
population, the provirus becomes part of
the genetic legacy of the species. It is
difficult to calculate exactly how many
retroviral infections of the germline led to
the ,100,000 copies of endogenous retro-
viruses in the human genome because
duplications, transpositions, and other
non-infectious events also contribute to
this number. However, at a very mini-
mum, each of the more than 31 families of
endogenous retrovirus found in the human
genome [1] must have arisen from one or
more separate paleoviruses that infected
the ancestors of modern humans. Since
reinfections of the germline with members
of the same families occurred frequently
[2], retroviral infections that impacted the
genome had to have happened repeatedly
during primate evolution with the most
recent episode in humans between
100,000 and 1 million years ago [3]
(Figure 1).
This impressive fossil record, represent-
ed by endogenous retroviruses, is still likely
a vast underestimate of the number of
retroviral infections of human ancestors.
Many retroviruses do not infect the germ-
line. For example, the human T cell
leukemia virus types I and II (HTLVI
and II) are thought to have entered human
populations over 20,000 years ago [4], but
no endogenous copies in human genomes
have yet been found. For those retrovirus-
es that do infect the germline, the majority
of integration events did not become fixed
since they were negatively selected out of
the population or lost by drift. Indeed, the
integration pattern of endogenous retrovi-
ruses (usually located away from genes) is
quite different from the integration pattern
of their exogenous counterparts (often
located near or in genes) [5,6], suggesting
that selection has cleansed the majority of
endogenization events from primate ge-
nomes. These imperfections in the fossil
record of endogenous retroviruses can lead
to vast underestimation of the age of viral
lineages, as was recently demonstrated for
the lentiviruses (retroviruses such as HIV-
1) where the finding of endogenized copies
in two independent lemur genera [7,8]
upwardly revised the age of primate
lentiviruses to more than 4 million years.
It has been challenging for paleovirol-
ogy to move beyond the study of endog-
enous retroviruses since it is much more
difficult to decipher ancient viruses that
left no extant copies of their past existence.
The recent finding that at least one
bornavirus gene has integrated in several
mammalian genomes at multiple evolu-
tionary periods demonstrates both the
possibility of identifying and dating some
other ancient classes of viral infections [9]
although this remains a rare event outside
of the retrovirus family. Nonetheless,
endogenous copies of viruses are but a
subset of the ancient and extinct viruses
that we call paleoviruses. The existence of
some additional paleoviruses can be deci-
phered by estimating the age of the last
common ancestor of extant viruses. For
viruses where there is evidence for co-
speciation of virus and host, we can arrive
at a conservative estimate of their evolu-
tionary age by correlation to the diver-
gence of their hosts. The best example of
primate viruses that have cospeciated with
its host over a considerable evolutionary
period are the spumaretroviruses [10]. For
other viruses, like herpesviruses and pap-
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for host–virus cospeciation [11,12].
In contrast, DNA viruses such as
orthopoxviruses show ample evidence of
host switching and have no suitable
cospeciation estimates. In such cases,
although we can calculate the time to the
last common ancestor from estimates of
mutation rates in extant sequences, this is
likely to be an underestimate due to the
extinction of viral lineages (and thus, the
loss of their sequence diversity in the
calculation) [13]. Moreover, these age
estimates do not provide any information
as to which host lineages might have been
affected by any given inferred paleovirus.
However, tracing the acquisitions of genes
and retroelements from host genomes into
large DNA viruses may provide an
additional means to estimate their diver-
gence times [14–16]. On the other hand,
the case for ancient RNA viruses, which
provide more examples of pathogenic
viruses than DNA viruses, is even more
vexing because high mutation rate essen-
tially obliterates bioinformatic signals and
our ability to meaningfully estimate an-
cestry beyond a few million years [13].
Indeed, based on mutation rates and
sampled lineages, one might incorrectly
infer that the last common ancestor for
most RNA viruses was very young [13].
Finding an Evolutionary Signal
of Ancient Infections within
Antiviral Genes
Given these problems in using the
sequences of current day viruses to identify
most paleoviruses, we propose another
approach to infer the existence of patho-
genic paleoviruses. This approach is based
on a striking evolutionary signature called
positive selection that these viruses impart
on antiviral genes in primate genomes.
When a viral infection rages in a popula-
tion, pre-existing variants of these antiviral
defense genes are acted upon by Darwin-
ian selection, leading to the accelerated
fixation of even previously rare variants in
the species. It is important to emphasize
that the inability to ward off a viral
infection can translate to significant fitness
costs. Therefore, beneficial variants in
antiviral genes will spread to fixation by
virtue of their significant selective advan-
tage even if viral infection does not lead to
death. Counterevolution by the virus (or
introduction of new viruses that evade the
host defenses using the same mechanisms)
eventually leads to renewed selective
pressure on antiviral genes. These recur-
rent bouts of selection represent evolution-
ary arms races that can be detected by
comparing DNA coding sequences of
related species and by using maximum
likelihood methods looking for excesses of
mutations that change amino acids in gene
sequences (non-synonymous mutations)
relative to mutations that do not change
amino acids (synonymous mutations) [17].
Repeated episodes of these arms races
between host antiviral genes and new viral
challenges will lead to dramatic rates of
change of non-synonymous mutations.
Thus, signatures of evolutionary changes
in protein-coding sequences of antiviral
genes allow us to infer the selection of
ancient host species due to paleoviruses.
Of course, it would be incorrect to
imply that the complete outcome of a viral
infection is decided on the basis of a single
host antiviral gene. If this were true, then
the differences in tempo of viral versus
host evolution would make it unlikely that
the hosts could ever adapt away from a
viral infection (Box 1). Instead, the host–
virus interaction is more complex, where
alleles in single host genes vary in relative
resistance/susceptibility to viruses. The
outcome of a particular viral infection on
a population level is determined by the
compendium of antiviral genes borne by
the host, the viral fitness cost associated
with escape from antiviral genes, as well as
many factors beyond host and viral
genetics. Nonetheless, over evolutionary
Figure 1. Time-line of paleoviruses in the human lineage. The dashed line at the top line
represents the time period for paleoviruses. The red lightning bolts represent dates of known
recent and ancient viruses based either on historical records, molecular clocks, or on endogenous
retroviruses in the human genome for SARS-Co [38], HIV-1 and -2 [39], dengue (DEN) [40], measles
[13], smallpox [41], HERV-K(HML2) [42], or PtERV [27], and older endogenous retroviruses shared
among all hominoids or all primates [43]. The blue, green, and orange lightning bolts represent
inferred viruses based on positive selection of TRIM5 [18], and the brown line is an inferred virus
based on positive selection of ZAP [19] simplified for representation, here. Each color corresponds
to inferred paleoviruses based on positive selection on a particular antiviral gene calculated on
the phylogenetic tree in the bottom of the figure where the lineage under selection has the same
color coding, and the dates correspond to dates of the ancestors [44]. Although one virus is
shown per episode of selection, there could be many different waves of similar viruses during that
time period. Purple branches refer to selections due to inferred paleoviruses in lineages that do
not lead directly to humans. There is considerable uncertainty associated with most of the dates
referred to in this figure.
doi:10.1371/journal.pbio.1000301.g001
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be discerned as long as beneficial alleles
confer fitness advantages to the host.
The comparison of sequence data from
multiple orthologs of primate antiviral
genes allows us to not only infer that a
given gene was under positive selection,
but also when it was under positive
selection. This can be done by recon-
structing the ancestral coding sequence of
an antiviral gene at each node of a primate
phylogenetic tree in silico and then
determining where positive selection oc-
curred on internal nodes (the internal
nodes can be dated by other molecular
evolutionary methods, assuming some sort
of molecular clock for mutation rates in
primate genomes, or by paleontological
fossil records). Each case of positive
selection for an antiviral gene on the
phylogenetic tree then implies the pres-
ence of at least one paleovirus on that
branch (Figure 1). For instance, since
diverging from the chimpanzee lineage,
human TRIM5, a potent antiviral factor,
has incurred eight non-synonymous and
two synonymous changes—this roughly
translates to an excess of three non-
synonymous changes over what might be
expected by chance [18]. This information
suggests the presence of at least one
paleovirus that was in genetic conflict with
TRIM5 in the 4–5 million years in the
human lineage since the human–chim-
panzee divergence (Figure 1). However,
there is no information about when each
of these three changes became fixed in the
population—this could have occurred in
rapid succession or slowly over 4–5 million
years. When the positive selection of
different unlinked antiviral genes are
compared to one another [18–21], one
finds different patterns of episodic positive
selection in primate evolution for each
gene. This suggests that different ancient
viral pathogens acting at different times
were responsible for driving selection of
one gene versus another. In theory,
episodes of positive selection could also
occur on multiple antiviral genes due to
the same pathogenic virus (Box 1) if the
fitness costs imposed by a particular virus
were especially severe at any given period
of primate evolution.
Another means to date a paleoviral
infection is the finding of a gene fusion
event in a particular primate lineage that
resulted in novel antiviral activity, exem-
plified by the TRIM5 fusion to a CypA
retrogene in the Aotus genus of New World
monkeys [22,23]. Dating the origin of such
a gene fusion can be informative even if
the ‘‘newly born’’ antiviral gene eventually
degrades due to relaxed selection (once the
paleoviral challenge is extinguished). In
both cases (positive selection or gene
fusions), the time-period under selection
can only be ascribed to a branch on the
evolutionary tree, which may represent
several million years of evolution (the age
represented by the branch is determined
by the phylogenetic density of extant
species and extent of sequence sampling).
Other methods can examine the positive
selection on antiviral genes in shorter time-
scales by looking for evidence of selective
sweeps using single nucleotide polymor-
phisms in modern population data, for
instance in human populations [24,25].
These methods are especially useful in
determining the action of a relatively
‘‘modern’’ selective pathogen which may
or may not also have had an ancient
counterpart. Finding both modern and
ancient selective episodes is strong indica-
tion of a particular antiviral gene having
been repeatedly acted upon by antago-
nism against both ancient paleoviruses and
present-day viral pathogens.
Challenges and Opportunities
in Using Evolution to Infer
Paleovirology
There are limitations to inferring epi-
sodes of paleoviral infection from signa-
tures of positive selection. Some weakness-
es in the method arise directly from
methodology; by definition, it is difficult,
if not impossible, to detect a single episode
of positive selection if it occurred in the
distant past. Thus, for the most part, we
are left considering only those antiviral
genes that have been repeated targets of
selection. Moreover, our ability to use
reconstructive evolution to infer positive
selection may weaken at deep evolutionary
distances, although the 35-million-year
age of simian primate evolution is espe-
cially tractable. An additional limitation is
the fact that the same antiviral gene may
have acted on different viruses over the
evolutionary record, with each new epi-
sode potentially ‘‘over-writing’’ the previ-
ous one. Each instance of adaptation may
involve only a few amino acid changes, but
if these occur at the same position then the
record can get muddled in terms of
elucidating exactly which change was
selected when. This limitation is exempli-
fied by the human major histocompatibil-
ity (MHC) class I genes devoted to the
presentation of viral antigens to the
adaptive immune system. The vast diver-
sity and rapid evolution of alleles in MHC
Class I demonstrates that humans and
primate ancestors have undergone dra-
matic episodes of positive selection to
protect against continual and diverse viral
attack [26]; however the constant turnover
has eroded information about all but the
most recently encountered viruses. Finally,
the evolutionary analysis of antiviral genes
that also play a role in limiting other
microbial pathogens would confound the
assessment of what type of pathogen was
responsible for the positive selection.
Notwithstanding these caveats, we be-
lieve it is possible to identify candidate
classes of paleoviruses based on analyses of
positive selection in antiviral genes (Box 1).
First, our knowledge of the functions of
antiviral genes under selection provides
clues to which viruses might be consid-
ered. For instance, some antiviral genes
are only active against a limited range of
viral lineages. Thus, ancient episodes of
positive selection in TRIM5 are likely
indicative of ancient retroviral infections
where the evolutionary loss of the ability of
Box 1: Problems in Paleovirology
What ancient viruses have caused selective pressure along the human lineage?
Is it possible to correlate evidence for ancient viruses with any other major
transitional events in the evolutionary history of animals or plants?
Do some viruses that were once eliminated from populations of human ancestors
have ecological reservoirs with the potential to be re-introduced into humans?
How do the different replication rates/mutation frequencies between viruses and
their hosts affect the population-level dynamics and evolutionary signatures of
genetic conflict on host genes?
What are the consequences of natural selections due to ancient viruses, or relaxed
selection due to loss of pathogenic pressure, on modern viral diseases?
Do certain types of antiviral genes show correlated positive selection along
certain branches of the primate phylogeny, suggesting their action against a
common pathogen?
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ancient selective events that changed the
specificity of TRIM5 clearly have had a
detrimental effect on the resistance of
modern humans to this contemporary
virus (Figure 2). Moreover, even when
the antiviral gene is embattled with several
viruses simultaneously, the amino acid
positions that have evolved under positive
selection can be a good indication of what
kind of antagonism was encountered
during a given evolutionary period. For
example, even through protein kinase R
can act as a general antiviral protein,
evolutionary reconstructions have allowed
us to infer the presence of virus-encoded
mimics of eIF2alpha throughout the
history of primate evolution, despite the
fact that such mimics are known in only a
few extant and relatively young lineages of
poxviruses and iridoviruses [21].
Second, since the rapid evolution of
host antiviral genes is likely driven by their
genetic conflict with specific viral antago-
nists, the classification of which modern
viruses can neutralize the function of
which antiviral genes under positive selec-
tion can help define classes of possible
candidate ancient viral antagonists and
thereby pathogens. Similarly, there may
be cases of ‘‘missing’’ viral species where
extinction of a virus that is present in sister
primate species could indicate the after-
math of a virus–host interaction that was
beneficial to one host lineage. Examples
include the PtERV retrovirus that is not
present in human genomes but is present
in chimpanzee and gorilla genomes [27], a
lineage of rhadinovirus that has not yet
been found in humans but is present in
sister taxa [28], and foamy viruses that are
present in most primates but not humans
[29]. Finding a human gene active against
a virus that is not found in humans could
be a starting point for considering whether
or not an older version of that virus was
eliminated from the evolutionary lineage
leading to modern humans due to ge-
netic adaptation rather than geographical
isolation.
What Paleovirology Can Tell Us
Why study pleovirology? Paleovirology
could be viewed as the study of ancient
viruses that primate genomes encountered
and defeated during the course of evolu-
tion. This view emphasizes that our
current antiviral repertoire was not opti-
mized to combat present infections, but
rather is the product of selection for
survival of our species’ past infections.
Thus, the selective changes that these
antiviral genes incurred during these
periods of evolutionary pressure might
make them less competent to fight modern
viral challenges (Figure 2; Box 1). For
example, the human TRIM5 gene does
not inhibit HIV, although it was certainly
selected to inhibit something else in our
past [30]. The analysis of amino acids on
antiviral genes driven by selection of
ancient pathogens can be used to identify
the interface between the host protein and
the virus (Figure 2) in ways that could
conceivably be used to design rational
antiviral drugs or gene therapy strategies.
Such analyses of the virus–host battles, on
an evolutionary scale, can also explain the
otherwise mysterious loss of antiviral
activities. For instance, antiviral genes that
serve no other cellular functions can incur
significant fitness costs or relaxed selection
and therefore can be lost due to the lack of
a pathogen during extended periods of
time [20,31]. These changes and losses to
our antiviral repertoire may help explain
deficiencies in our current innate immune
protection against pathogenic viral chal-
lenges.
The study of ‘‘resurrected’’ paleoviruses,
exemplified by the evolution-guided re-
construction of several endogenous retro-
viruses and the 1918 influenza virus [32–
36] can also reveal previously hidden
details of host–virus interactions. Finally,
the universe of possible ‘‘emerging virus-
es’’ that could arise by cross-species
transmission of viruses from other animals
into humans [37] is still largely undefined.
It is possible that amidst this reservoir of
potential pathogens lie the descendants of
viruses that were once eliminated from
human ancestors, but because of contin-
ued evolution of both virus and humans
could now reinfect modern humans.
Although we have focused on paleoviruses
of humans and primate ancestors in this
essay, the same arguments can be made
and lines of research can be applied to
nearly any set of animal or plant families
for which virus–host relationships exist.
Paleovirology, in this broader sense, may
be able to correlate the existence of
ancient infections with known phylogeo-
graphical events, such as extinctions,
bursts of speciation, exchanges of fauna
between continents, island isolations, and
population migrations (Box 1). We look
forward to further community efforts to
identify candidate paleoviruses, analyze
the evolutionary signatures of suspected
paleoviral infections, and determine how
these ancient evolutionary battles have
affected our ability to combat new and
recurrent viral diseases of humans.
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Figure 2. TRIM5 restriction of HIV-1 has decreased during evolution leading to
humans. The shading of the rectangle represents the degree that TRIM5 will limit infection of
HIV-1 (darker color means TRIM5 decreases HIV-1 infection more) and the X-axis indicates time in
millions of years from the present. Each dotted line represents the reconstruction of TRIM5 as it
likely existed at a node of a phylogenetic tree indicating a common ancestor of humans with
chimpanzees, gorillas, orangutans, gibbons, and Old World monkeys (rhesus). Original data is
found in [30] and shows that the antiviral gene TRIM5 restricted HIV-1 better at points in
evolution earlier than the chimp–human common ancestor than it does after that. On the right
shows an amino acid sequence of a region of TRIM5 containing amino acids that confer resistance
or susceptibility to HIV-1 with the amino acids that are under the strongest positive selection in
red [14]. Changes in this region cause a gain of restriction to some viruses, while causing a loss to
others [33,45–47]. The R332 amino acid, which represents the single largest determinant of loss of
resistance to HIV-1 [48,49], was fixed before the chimp–human common ancestor, but positive
selection has continued in TRIM5 along the human lineage beyond this point.
doi:10.1371/journal.pbio.1000301.g002
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